ERBB2 and neoplasm: These have proven to be capable of eliciting tumor-specific cytotoxicity, as demonstrated by human epidermal growth factor receptor 2 (HER2)-specific CARs using scFv recognizing HER2 fused to a CD3ζ signaling domain for activation (signal 1) (135, 136).